Observational real world study of effectiveness of pazopanib in RCC
Research type
Research Study
Full title
A prospective, observational study to evaluate the real world effectiveness and safety of available treatment patterns in patients with advanced and/or metastatic renal cell carcinoma previously or currently treated with pazopanib
IRAS ID
231041
Contact name
Minnie Mildwoff
Contact email
Sponsor organisation
Novartis Pharma AG
Clinicaltrials.gov Identifier
2017‐001720‐21, EudraCT number
Duration of Study in the UK
5 years, 11 months, 27 days
Research summary
New medicines for kidney cancer (renal cell carcinoma) are continually being identified and there are anticipated changes to the treatment patterns of kidney cancer now and within the next few years. This study seeks to gather information about how pazopanib and newer medicines are used to treat kidney cancer and the effectiveness and safety of the available treatment patterns. This is an observational study meaning that no study specific procedures or study visits will be performed and no study medication is provided. After the patient has given permission to do so, information will be collected from the patient's medical records about the previous and ongoing medical treatment of their cancer. Patients will either be currently taking or have finished taking pazopanib within three months before consenting to this study, whereupon historical information about the diagnosis, treatment and patients health will be collected from their medical records, and their future medications and health will be followed up by review of their medical records for the duration of the study (for at least two years and no longer than five years).
REC name
South Central - Oxford C Research Ethics Committee
REC reference
17/SC/0453
Date of REC Opinion
18 Aug 2017
REC opinion
Further Information Favourable Opinion